US · Healthcare · Biotechnology
EPS came in at -0.14 against a street estimate of -0.12 — a miss of 16.7%.
Analysts rate Erasca Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $24.11.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 7.14% |
| T. Rowe Price Investment Management,Inc. | 6.06% |
| BlackRock Inc | 6.05% |
| RTW INVESTMENTS, LLC | 5.13% |
| VR Adviser, LLC | 5.12% |
| State Street Corp | 3.48% |
| Logos Global Management LP | 3.47% |
| Vanguard Capital Management, LLC | 3.26% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • Erasca is realigning leadership responsibilities to support the development and potential commercialization of its RA | 2026-10-16 |
| Company announcement · Q3 2026 ERASCA, INC. (ERAS) — 8-K SUMMARY HEADLINE NUMBERS • Company: Erasca, Inc., a biopharmaceutical company based in San Diego, California • Ticker: ERA | 2026-08-24 |
| Quarterly report · Q2 2026 ERASCA, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash & Securities Position (June 30, 2026): $384.3 million total ($42.5 million cash + $226 | 2026-08-11 |
| Results announced · Q3 2026 ERASCA, INC. - Q2 2026 FINANCIAL & BUSINESS SUMMARY HEADLINE NUMBERS • Cash Position: $384.3 million in cash, cash equivalents, and marketable secur | 2026-08-11 |
| Board / officer change · Q3 2026 ERASCA, INC. - 8-K FILING SUMMARY (August 10, 2026) HEADLINE NUMBERS • Charles S. Fuchs, M.D., M.P.H. appointed as President, Research & Development | 2026-08-10 |
| Company announcement · Q3 2026 ERASCA, INC. (ERAS) – 8-K SUMMARY HEADLINE NUMBERS • Stock offering size: 31,428,572 shares at $17.50 per share to the public • Underwriter purchase | 2026-07-14 |
| Quarterly report · Q1 2026 ERASCA, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $408.5 million as of March 31, 2026 ($276.8 million in cash and | 2026-05-11 |
| Proxy statement · Q2 2026 ERASCA, INC. – 2026 ANNUAL MEETING PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class II directors for three-year terms e | 2026-04-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Clinical trial collaboration and supply agreement entered with Merck Erasca, a clinical-stage oncology company, reported encouraging progress on its lead drug ERAS-0015, a treatment for RAS-driven cancers. Key highlights: ERAS-0015 showed strong efficacy and | 2026-05-11 |
| Phase 1 monotherapy data readout timing narrowed to mid-May 2026 Erasca, Inc. announced on April 21, 2026 that it has narrowed the timeline for releasing Phase 1 clinical trial results for its lead drug candidate ERAS-0015, a pan-RAS molecular glue treatm | 2026-04-21 |
| Phase 1 monotherapy data expected H1 2026 for ERAS-0015, H2 2026 for ERAS-4001 Erasca, a clinical-stage cancer drug company, reported encouraging early results for its lead drug ERAS-0015, a RAS-targeting therapy. The company observed partial responses across multiple | 2026-03-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Erasca Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.